Bharat Parenterals gets DCGI nod for favipiravir oral suspension

Equity Wizard May 22, 2021 Real Estate

The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.

via Economictimes

No comments

Subscribe to: Post Comments ( Atom )